The predementia diagnosis of Alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 18, Issue 2, 2004, Pages 51-53

  Frisoni, Giovanni B ^a   Padovani, Alessandro ^b   Wahlund, Lars Olof ^c  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; AGING; ALZHEIMER DISEASE; COGNITIVE DEFECT; DIAGNOSTIC ACCURACY; EDITORIAL; HUMAN; PREDICTION; PRIORITY JOURNAL; RISK FACTOR;

ALZHEIMER DISEASE; COGNITION DISORDERS; DISEASE PROGRESSION; HUMANS; MENTAL RECALL; NEUROPSYCHOLOGICAL TESTS; RISK ASSESSMENT;

EID: 2942537696     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wad.0000126613.05674.0c     Document Type: Editorial

References (22)

1. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303-308.
2. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985-1992.
3. Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58:397-405.
4. Mufson EJ, Chen EY, Cochran EJ, et al. Entorhinal cortex beta-amyloid load in individuals with mild cognitive impairment. Exp Neurol. 1999; 158:469-490.
5. Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59:198-205.
6. Larrieu S, Letenneur L, Orgogozo JM, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology. 2002;59:1594-1599.
7. Fisk JD, Merry HR, Rockwood K. Variations in case definition affect prevalence but not outcomes of mild cognitive impairment. Neurology. 2003;61:1179-1184.
8. Okamura N, Arai H, Maruyama M, et al. Combined analysis of CSF tau levels and [(123)I]Iodoamphetamine SPECT in mild cognitive impairment: implications for a novel predictor of Alzheimer's disease. Am J Psychiatry. 2002;159:474-476.
9. Meyer JS, Xu G, Thornby J, et al. Longitudinal analysis of abnormal domains comprising mild cognitive impairment (MCI) during aging. J Neurol Sci. 2002;201:19-25.
10. Jack CR Jr, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52: 1397-1403.
11. Bosscher L, Scheltens PH. MRI of the medial temporal lobe for the diagnosis of Alzheimers' disease. In: Qizilbash N, Schneider LS, Chui H, et al, eds. Evidence-Based Dementia Practice. Oxford: Blackwell, 2002:154-161.
12. Buerger K, Teipel SJ, Zinkowski R, et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology. 2002;59:627-629.
13. Riemenschneider M, Lautenschlager N, Wagenpfeil S, et al. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol. 2002;59;1729-1734.
14. Arnaiz E, Jelic V, Almkvist O, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport. 2001;12:851-855.
15. Chetelat G, Desgranges B, De La Sayette V, et al. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology. 2003;60:1374-1377.
16. El Fakhri G, Kijewski MF, Johnson KA, et al. MRI-guided SPECT perfusion measures and volumetric MRI in prodromal Alzheimer disease. Arch Neurol. 2003;60:1066-1072.
17. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
18. Chui H, Lee A. Clinical criteria for dementia subtypes. In: Qizilbash N, Schneider LS, Chui H, et al, eds. Evidence-Based Dementia Practice. Oxford: Blackwell, 2002:106-118.
19. Ritchie K, Artero S, Touchon J. Classification criteria for mild cognitive impairment: a population-based validation study. Neurology. 2001;56: 37-42.
20. Andreasen N, Vanmechelen E, Vanderstichele H, et al. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand Suppl. 2003;179:47-51.
21. Kantarci K, Jack CR Jr, Xu YC, et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: a 1H MRS study. Neurology. 2000;55:210-217.
22. Padovani A, Borroni B, Colciaghi F, et al. Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease. Arch Neurol. 2002;59:71-75.